<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>8588730</identifier>
<setSpec>0004-0614</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Jiménez, F J</dc:author>
<dc:author>López Alvarez, Y J</dc:author>
<dc:author>Sánchez-Chapado, M</dc:author>
<dc:author>Angulo Cuesta, J</dc:author>
<dc:author>Guil Cid, M</dc:author>
<dc:description xml:lang="en">OBJECTIVES The present study describes two patients with retroperitoneal fibrosis following prolonged use of bromocriptine and pergolide for Parkinson's disease. Both patients also presented severe atheromatosis. METHODS Similar cases reported in the literature are reviewed and the possible relationship between the use of the ergotamine derivate and severe atheromatosis is discussed. RESULTS Both patients, a 67-year-old male and a 62-year-old female, improved after discontinuing bromocriptine, despite severe damage of renal function. CONCLUSIONS Retroperitoneal fibrosis may develop in patients with bilateral ureteral obstruction, especially those who have received drugs that have been reported to cause the foregoing condition.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>1995 Dec </dc:date>
<dc:title xml:lang="es">Fibrosis retroperitoneal secundaria a tratamiento con análogos de L-dopa por enfermedad de Parkinson.</dc:title>
<dc:title xml:lang="en">[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].</dc:title>
<dc:publisher>Archivos espanoles de urologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
